Abdel-Wahab Lab Profile picture
Apr 12, 2021 10 tweets 7 min read Read on X
We are excited to announce our paper in @NatureGenet uncovering a role for minor introns in clonal hematopoietic disorders, Noonan Syndrome, and a diverse number of cancers. A collaboration between our lab (@sloan_kettering) and @bradleybio (@fredhutch): nature.com/articles/s4158…
2.Most eukaryotes have 2 splicing machineries: the major & minor spliceosome. The minor spliceosome recognizes <0.5% of the introns in the human genome. Since their discovery, biological roles for minor introns have been enigmatic.
3.In work co-led by @DaichiInoue5, Jacob Polaski, and @TaylorJ_MD we identify that deletion of the minor spliceosome regulatory protein ZRSR2, frequently mutated in MDS and AML, enhances hematopoietic stem cell self-renewal.
4.We mapped ZRSR2 responsive introns across patients and mouse hematopoietic cells using RNA-seq and anti-ZRSR2 eCLIP-seq to find a subset of ZRSR2 regulated introns.
5.Beautiful work from Jose Pineda @bradleybio identified unique branchpoint features of ZRSR2 regulated introns. Please see Jose’s prior great paper in @GenesDev:
genesdev.cshlp.org/content/early/…
6.We then performed a CRISPR functional enrichment screen to identify those ZRSR2 regulated splicing events which may be associated with clonal advantage in hematopoietic cells.
7.This revealed a surprising discovery of mis-splicing of the minor intron of the CUL3 adaptor regulating RAS GTPas abundance LZTR1 in ZRSR2-mutant MDS and AML.
8.With wonderful help from @castel_pau & the Frank McCormick lab (@frankpmccormick) we found that mutations within LZTR1’s minor intron itself was transforming to hematopoietic cells and present in Noonan Syndrome (@noonansyndrome, @Noonan_Syndrome) as well as Schwannomatosis.
9.Moreover, in analyzing LZTR1 minor intron regulation across the pan-can #TCGA dataset, @chewomics (@csi_singapore) identified widespread impaired LZTR1 minor intron excision across cancers (the basis for which we are actively working to understand now):
10.Thanks to funding for Rob and I from the @EdwardPEvansFdn, @theNCI, @nih_nhlbi, and @CDMRP

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdel-Wahab Lab

Abdel-Wahab Lab Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AbdelWahablab

Jul 30, 2022
Excited to announce a new paper in @CD_AACR on genetic, biological & therapeutic implications of mutations impacting degradation of RAS proteins in clonal hematopoietic disorders. Led by @_SisiChen and collaboration with @castel_pau and @ColemanLindsley
aacrjournals.org/cancerdiscover…
We identify that loss of LZTR1, an adaptor of a Cullin-3 RING E3 ubiquitin ligase complex responsible for degradation of RAS GTPases drive hematopoietic stem cell expansion and leukemia in vivo.
LZTR1 loss upregulates non-canonical RAS GTPases RIT1 and MRAS in hematopoietic tissue and we also identify that leukemia-associated mutants RIT1 which escape LZTR1-mediated degradation, similarly result in myeloid neoplasms.
Read 7 tweets
Feb 23, 2022
It is a pleasure to announce our publication in @NEJM discovering resistance to non-covalent BTK inhibitors in patients with CLL. A collaborative effort with @anthonymatomd and @TaylorJ_MD led by @ewang2323, Xiaoli Mi, and @MCThompsonMD. nejm.org/doi/full/10.10…
Non-covalent BTK inhibitors are promising therapies for CLL patients as they overcome the BTK C481 mutations which cause resistance to covalent BTK inhibitors such as ibrutinib. Previously however, resistance mechanisms to non-covalent BTK inhibitors in patients were unknown.
Thanks to @anthonymatomd leadership in trials of pirtobrutinib (thelancet.com/article/S0140-…), we applied bulk & single cell genomic assays (thank you @MissionBio) to identify acquired BTK mutations outside of the C481 residue, associated with clinical resistance to pirtobrutinib.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(